Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Djordje Atanackovic, Tim Luetkens, Destiny Omili, Thierry Iraguha, Forat Lutfi, Nancy M. Hardy, Xiaoxuan Fan, Stephanie V. Avila, Kapil K. Saharia, Jennifer S. Husson, Silke V. Niederhaus, Philip Margiotta, Seung T. Lee, Jennie Y. Law, Heather D. Mannuel, Erica Vander Mause, Sherri Bauman, Patricia Lesho, Kim Hankey, John Baddley, Mehmet Kocoglu, Jean A. Yared, Aaron P. Rapoport, Saurabh Dahiya
Publikováno v:
Blood. 140:152-156
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al d
Autor:
Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith
Publikováno v:
Blood. 140:6594-6595
Autor:
David Tong Chen, Olga Goloubeva, Hanan Alkhaldi, Aaron P. Rapoport, Saurabh Dahiya, Nancy M. Hardy, Djordje Atanackovic, Mehmet Hakan Kocoglu, Forat Lutfi, Jean A. Yared
Publikováno v:
Blood. 140:9526-9527
Publikováno v:
Blood
Introduction: Standard induction therapy for multiple myeloma consists of 3-6 cycles of bortezomib, lenalidomide, and dexamethasone (VRd) or carfilzomib, lenalidomide and dexamethasone (KRd). Receiving greater than 6 cycles of a lenalidomide containi
Autor:
Nancy M. Hardy, Kim G. Hankey, Seung Tae Lee, Aaron P. Rapoport, Mehmet Hakan Kocoglu, Nancy Smith, Tim Luetkens, Patricia Lesho, Sherri Bauman, Djordje Atanackovic, Jean A. Yared, Kathleen Ruehle, John W Baddley, Philip Margiotta, Stephanie Avila, Jennie Y. Law, Saurabh Dahiya
Publikováno v:
Blood
Introduction: Patients with hematologic malignancies are at an increased risk of morbidity and mortality from COVID-19 disease (Vijenthira, Blood 2020). This is likely a result of combination of immunodeficiency conferred by the disease and the thera
Autor:
Jay Y. Spiegel, Saurabh Dahiya, Khoan Vu, Miriam T. Jacobs, Abhinav Deol, Kathleen A. Dorritie, N. Nora Bennani, Julie M. Vose, David B. Miklos, Patrick M. Reagan, Matthew A. Lunning, Armin Ghobadi, Aaron P. Rapoport, Frederick L. Locke, Loretta J. Nastoupil, Charalambos Andreadis, John S. Tamaresis, Yi Lin, Michael D. Jain, Brian T. Hill, Joseph P. McGuirk, Olalekan O. Oluwole, Sattva S. Neelapu, Andre Goy, Javier Munoz, Lazaros J. Lekakis
Publikováno v:
Blood
Autor:
James E. Hoffman, Taiga Nishihori, Michael Chisamore, Stefan Zajic, Jonathan L. Kaufman, Sunil Suchindran, Aaron P. Rapoport, Charlotte Snape, Anne Huff, Gurpreet Kapoor, Amit Jain
Publikováno v:
Blood. 138:3865-3865
Background: Outcomes remain poor for patients with relapsed and refractory multiple myeloma (RRMM) progressing on conventional therapy (proteasome inhibitors, IMiDs, anti-CD38 antibodies, BCMA targeting agents, corticosteroids). Lete-cel, an autologo
Autor:
Lazaros J. Lekakis, Sattva S. Neelapu, Andre Goy, Jay Y. Spiegel, John S. Tamaresis, Julio C. Chavez, Saurabh Dahiya, Julie M. Vose, Aaron P. Rapoport, Patrick M. Reagan, Joseph P. McGuirk, Alison R. Sehgal, Olalekan O. Oluwole, Charalambos Andreadis, Abhinav Deol, Matthew A. Lunning, Yi Lin, Brian T. Hill, Armin Ghobadi, Miriam T. Jacobs, Jason R. Westin, N. Nora Bennani, Michael D. Jain, Frederick L. Locke, Matthew L. Ulrickson, Loretta J. Nastoupil, Javier Munoz, David B. Miklos
Publikováno v:
Blood. 138:3826-3826
Introduction: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy that induces durable responses in patients with relapsed or refractory large B-cell lymphoma. At a median of 27.1 months follow-
Autor:
Abhinav Deol, Amer Beitinjaneh, Trent P Wang, Brian T. Hill, Sattva S. Neelapu, Aaron P. Rapoport, Frederick L. Locke, Yi Lin, Jonas Paludo, Preetesh Jain, Matthew J. Frank, Lazaros J. Lekakis, Miriam T. Jacobs, Bijal D. Shah, Julie M. Vose, Andre Goy, Saurabh Dahiya, Armin Ghobadi, Javier Munoz, Yucai Wang, David B. Miklos, Michael Wang, Joseph P. McGuirk, Matthew J. Maurer, Olalekan O. Oluwole, Michael D. Jain
Publikováno v:
Blood. 138:744-744
Introduction: Brexucabtagene autoleucel (brexu-cel) was approved by US FDA for relapsed/refractory (R/R) mantle cell lymphoma (MCL) on July 24, 2020 based on results from the pivotal ZUMA-2 (NCT02601313) study, in which an objective response rate (OR
Autor:
Lisa R Matsumoto, Forat Lutfi, Nancy M. Hardy, Mehmet Hakan Kocoglu, Seung Tae Lee, Saurabh Dahiya, Jennie Y. Law, Dong Won Kim, Djordje Atanackovic, David Gottlieb, Philip Margiotta, Olga Goloubeva, Amer Kowatli, Caroline Dunne, Wengen Chen, Kathleen Ruehle, Anton A. Gryaznov, Ali Bukhari, Aaron P. Rapoport, Jean A. Yared
Publikováno v:
Blood. 138:3876-3876
Introduction: CD19 Chimeric Antigen Receptor T-cell (CAR-T) therapy is now a commonly used treatment for relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL). However, predictors of long-term response remain poorly defined. In particular, partial r